MX2018008321A - Tratamiento de tumores ocasionados por disfuncion metabolica. - Google Patents
Tratamiento de tumores ocasionados por disfuncion metabolica.Info
- Publication number
- MX2018008321A MX2018008321A MX2018008321A MX2018008321A MX2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- metabolic dysfunction
- tumors driven
- driven
- present disclosure
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000003818 metabolic dysfunction Effects 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277293P | 2016-01-11 | 2016-01-11 | |
| US201662393929P | 2016-09-13 | 2016-09-13 | |
| US201662395446P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/012968 WO2017123603A1 (en) | 2016-01-11 | 2017-01-11 | Treatment for tumors driven by metabolic dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008321A true MX2018008321A (es) | 2018-09-21 |
Family
ID=57882196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008321A MX2018008321A (es) | 2016-01-11 | 2017-01-11 | Tratamiento de tumores ocasionados por disfuncion metabolica. |
| MX2023002076A MX2023002076A (es) | 2016-01-11 | 2018-07-04 | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002076A MX2023002076A (es) | 2016-01-11 | 2018-07-04 | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10646463B2 (enExample) |
| EP (1) | EP3402529A1 (enExample) |
| JP (3) | JP7022066B2 (enExample) |
| KR (2) | KR102934569B1 (enExample) |
| CN (2) | CN114225045B (enExample) |
| AU (3) | AU2017206718B2 (enExample) |
| CA (2) | CA3008960C (enExample) |
| MX (2) | MX2018008321A (enExample) |
| WO (1) | WO2017123603A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| EP3574922B1 (en) | 2013-04-10 | 2021-09-15 | Syndevrx, Inc. | Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity |
| KR102849342B1 (ko) | 2015-12-10 | 2025-08-21 | 신데브알엑스, 인크. | 푸마길롤 유도체 및 그의 다형체 |
| AU2017206718B2 (en) * | 2016-01-11 | 2021-09-30 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| US11612577B2 (en) | 2018-10-26 | 2023-03-28 | Syndevrx, Inc. | Biomarkers of METAP2 inhibitors and applications thereof |
| CN112915210B (zh) * | 2019-12-06 | 2024-08-20 | 重庆阿普格雷生物科技有限公司 | 一种聚乙二醇偶联药物、其制备方法及应用 |
| CN116887836A (zh) * | 2020-11-11 | 2023-10-13 | 辛德弗雷克斯公司 | 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合 |
| AU2021378944A1 (en) * | 2020-11-11 | 2023-06-15 | Syndevrx, Inc. | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
| EP4568706A1 (en) * | 2022-08-10 | 2025-06-18 | Syndevrx, Inc. | Metap2 inhibitors for the treatment of pulmonary fibrosis |
| EP4618970A1 (en) * | 2022-11-16 | 2025-09-24 | Syndevrx, Inc. | Metap2 inhibitors for the treatment of prostate cancer |
| CN119932197B (zh) * | 2025-04-09 | 2025-06-13 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2803586A (en) | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
| US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| US20020076442A1 (en) | 1997-09-02 | 2002-06-20 | Martin Burke | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| DE69824750T2 (de) | 1997-10-31 | 2005-07-07 | Children's Medical Center Corp., Boston | Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe |
| CO5021134A1 (es) * | 1998-05-01 | 2001-03-27 | Abbott Lab | Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina |
| SK16282000A3 (sk) | 1998-05-01 | 2001-05-10 | Abbott Laboratories | Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2 |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| WO1999061061A1 (fr) | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
| US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
| MXPA01004239A (es) | 1998-10-30 | 2002-06-04 | Daiichi Seiyaku Co | Compuesto dds y metodo para la medicion del mismo. |
| JP4883515B2 (ja) | 1999-09-08 | 2012-02-22 | ポリセリックス リミテッド | 均一分子量ポリマー |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| ATE440094T1 (de) | 2001-09-27 | 2009-09-15 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| US20040005641A1 (en) | 2002-02-15 | 2004-01-08 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| JP4514455B2 (ja) | 2002-04-11 | 2010-07-28 | チルドレンズ メディカル センター コーポレーション | Ｔｎｐ−４７０ポリマー複合体及びその使用 |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
| US20080248030A1 (en) | 2005-02-02 | 2008-10-09 | Children's Medical Center Corporation | Method of Treating Angiogenic Diseases |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム |
| WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| AU2008321382A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| WO2009064738A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| AU2008335469A1 (en) | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| EP2307032A4 (en) | 2008-05-22 | 2014-08-20 | Univ Ramot | NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| BR112012016793A2 (pt) * | 2010-01-08 | 2018-07-31 | Zafgen Corp | compostos tipo fumagilol e métodos de fazer e usar os mesmos |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| US20130137831A1 (en) | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| WO2011150022A2 (en) * | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| EP2786755A3 (en) | 2010-11-12 | 2014-10-29 | Pharma Mar S.A. | Combination therapy with an antitumor alkaloid |
| AU2012225531B2 (en) | 2011-03-08 | 2017-03-30 | Zafgen, Inc | Oxaspiro (2.5) octane derivatives and analogs |
| EP3574922B1 (en) * | 2013-04-10 | 2021-09-15 | Syndevrx, Inc. | Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity |
| EP4772247A2 (en) | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| KR102849342B1 (ko) | 2015-12-10 | 2025-08-21 | 신데브알엑스, 인크. | 푸마길롤 유도체 및 그의 다형체 |
| AU2017206718B2 (en) * | 2016-01-11 | 2021-09-30 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| MX2019001467A (es) | 2016-08-03 | 2019-10-02 | Remd Biotherapeutics Inc | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. |
| US11612577B2 (en) | 2018-10-26 | 2023-03-28 | Syndevrx, Inc. | Biomarkers of METAP2 inhibitors and applications thereof |
-
2017
- 2017-01-11 AU AU2017206718A patent/AU2017206718B2/en active Active
- 2017-01-11 US US15/403,675 patent/US10646463B2/en active Active
- 2017-01-11 KR KR1020187022956A patent/KR102934569B1/ko active Active
- 2017-01-11 WO PCT/US2017/012968 patent/WO2017123603A1/en not_active Ceased
- 2017-01-11 CA CA3008960A patent/CA3008960C/en active Active
- 2017-01-11 CN CN202111316615.1A patent/CN114225045B/zh active Active
- 2017-01-11 MX MX2018008321A patent/MX2018008321A/es unknown
- 2017-01-11 EP EP17701409.9A patent/EP3402529A1/en active Pending
- 2017-01-11 CA CA3239447A patent/CA3239447A1/en active Pending
- 2017-01-11 KR KR1020267006377A patent/KR20260036617A/ko active Pending
- 2017-01-11 CN CN201780016316.1A patent/CN108697807B/zh active Active
- 2017-01-11 JP JP2018536151A patent/JP7022066B2/ja active Active
-
2018
- 2018-07-04 MX MX2023002076A patent/MX2023002076A/es unknown
-
2020
- 2020-05-07 US US16/868,693 patent/US11273142B2/en active Active
-
2021
- 2021-12-17 AU AU2021286420A patent/AU2021286420B2/en active Active
-
2022
- 2022-02-04 JP JP2022016251A patent/JP7640481B2/ja active Active
- 2022-03-14 US US17/693,478 patent/US20220280470A1/en active Pending
-
2024
- 2024-06-13 AU AU2024204027A patent/AU2024204027B2/en active Active
-
2025
- 2025-02-20 JP JP2025025705A patent/JP2025071236A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11273142B2 (en) | 2022-03-15 |
| US10646463B2 (en) | 2020-05-12 |
| CA3008960C (en) | 2024-07-02 |
| JP7022066B2 (ja) | 2022-02-17 |
| JP2022048388A (ja) | 2022-03-25 |
| US20220280470A1 (en) | 2022-09-08 |
| JP2025071236A (ja) | 2025-05-02 |
| CN108697807A (zh) | 2018-10-23 |
| KR20260036617A (ko) | 2026-03-17 |
| CA3239447A1 (en) | 2017-07-20 |
| CN108697807B (zh) | 2021-11-26 |
| AU2021286420B2 (en) | 2024-03-14 |
| AU2017206718B2 (en) | 2021-09-30 |
| EP3402529A1 (en) | 2018-11-21 |
| KR102934569B1 (ko) | 2026-03-04 |
| US20170196830A1 (en) | 2017-07-13 |
| JP7640481B2 (ja) | 2025-03-05 |
| JP2019501206A (ja) | 2019-01-17 |
| WO2017123603A1 (en) | 2017-07-20 |
| AU2024204027B2 (en) | 2026-06-04 |
| US20210077452A1 (en) | 2021-03-18 |
| MX2023002076A (es) | 2023-03-17 |
| KR20180100663A (ko) | 2018-09-11 |
| AU2021286420A1 (en) | 2022-01-20 |
| CA3008960A1 (en) | 2017-07-20 |
| AU2024204027A1 (en) | 2024-07-04 |
| AU2017206718A1 (en) | 2018-07-05 |
| CN114225045B (zh) | 2025-09-26 |
| CN114225045A (zh) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002076A (es) | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. | |
| PH12019501959A1 (en) | Therapeutic rna | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MX2023004221A (es) | Inhibidores de rad51. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| TW201613882A (en) | Histone demethylase inhibitors | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| MX2023011187A (es) | Metodos para tratar el cancer de prostata. | |
| MY194341A (en) | Method of treating a brain tumor | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| HK1258319A1 (zh) | 癌症疗法 | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| EA201791814A1 (ru) | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| PH12021551419A1 (en) | New conjugated nucleic acid molecules and their uses | |
| WO2016106357A8 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| MX2020011766A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| EA201650085A1 (ru) | Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида | |
| MX2017000087A (es) | Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer. |